Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | KCNT1 | Q5JUK3 | 4/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454397 | 0.81 | PSMB8 (0.46) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL2215374 | 0.81 | KDM4E (0.50) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL2363430 | 0.80 | FAAH (0.49) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL4072006 | 0.80 | PSMB8 (0.45) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL3065968 | 0.80 | KCNT1 (0.46) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL17452576 | 0.77 | PSMB8 (0.49) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL15273648 | 0.77 | PSMB8 (0.46) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL8031275 | 0.75 | PSMB8 (0.53) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL11899894 | 0.75 | PSMB8 (0.50) | PSMB8PSMB9PSMB5CACNA1HKCNT1 | |
| SCHEMBL17162239 | 0.75 | FAAH (0.50) | PSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | PSMB8 3467/4885PSMB9 3912/4885PSMB5 3158/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | PSMB8 3467/4885PSMB9 3912/4885PSMB5 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.